Previous 10 | Next 10 |
My previous article forecast problems for selonsertib, as new research indicates that this drug targets mouse-specific pathways that are not present in humans. NASH cirrhosis trials continue to struggle. Intercept’s Ocaliva, a “NASH cirrhosis” drug candidate, is haile...
Editor's note: Seeking Alpha is proud to welcome Richelle Cutler-Strom as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » The...
Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...
Market Assessment 2019 is seen as the year of NASH in the biotech industry. Intercept ( ICPT ) is expected to announce the top-line Phase 3 data readout for obeticholic acid in NASH fibrosis imminently. Likewise, top-line data readout is also expected in Q1/2019 from Conatus ( CNAT ). This s...
My Analysis Intercept Pharmaceuticals ( ICPT ) became biotechnologically famous in 2014 with its stock blasting off financially to a place no liver therapeutics stock had ever been. Since then, this mid-cap ($3.52B) biopharma has had to deal with the clinical scrutiny that typically occurs a...
Clinical Trials NASH is a progressive chronic liver disease with many causal pathogenic factors. We have learnt from research that dysregulation of the glucose and lipid metabolic pathways could be associated with the development of NASH. Inflammation and activation of the apoptotic (i.e. ce...
Intercept Pharmaceuticals (NASDAQ: ICPT ) is up 4% premarket on light volume in apparent reaction to an upgrade to Strong Buy at Raymond James citing the likelihood of an FDA nod for obeticholic acid in NASH. More news on: Intercept Pharmaceuticals Read more ...
NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged at 2.25% to 2.50%. The Dow Jones Industrial Average went higher by 1.77 percent to ...
For the better part of the past year, the narrative surrounding Intercept Pharmaceuticals ( ICPT ) has been the potential of its Ocaliva as a treatment for NASH… nonalcoholic steatohepatitis. And, that’s been the case for good reason. The company’s clinical trials of the d...
Amicus Therapeutics (NASDAQ: FOLD ) initiated with Overweight rating and $20 (76% upside) price target at Cantor Fitzgerald. Shares up 2% premarket. More news on: Amicus Therapeutics, Inc., Intercept Pharmaceuticals, Allergan plc, Healthcare stocks news, Stocks on the move, , ...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...